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Abstract
Objective—To compare the accuracy of linkage to care metrics for patients diagnosed with HIV 
using retention in care and virologic suppression as the gold standards of effective linkage.
Design—A retrospective cohort study of patients aged 18 and over with newly-diagnosed HIV 
infection in the City of Philadelphia, 2007 to 2008.
Methods—Times from diagnosis to clinic visits or laboratory testing were used as linkage 
measures. Outcome variables included being retained in care and achieving virologic suppression, 
366-730 days after diagnosis. Positive predictive value (PPV), negative predictive value (NPV), 
and area under the curve (AUC) for each linkage measure and retention and virologic suppression 
outcomes are described.
Results—Of the 1781 patients in the study, 503 (28.2%) were retained in care in the Ryan White 
system and 418 (23.5%) achieved virologic suppression 366-730 days after diagnosis. The linkage 
measure with the highest PPV for retention was having two clinic visits within 365 days of 
diagnosis, separated by 90 days (74.2%). Having a clinic visit between 21 and 365 days after 
diagnosis had both the highest NPV for retention (94.5%) and the highest adjusted AUC for 
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retention (0.872). Having two tests within 365 days of diagnosis, separated by 90 days, had the 
highest adjusted AUC for virologic suppression (0.780).
Conclusions—Linkage measures associated with clinic visits had higher PPV and NPV for 
retention, while linkage measures associated with laboratory testing had higher PPV and NPV for 
retention. Linkage measures should be chosen based on the outcome of interest.
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HIV; linkage to care; retention in care; virologic suppression; HIV care cascade; engaging in care
Introduction
Persons living with HIV (PLWH) must fulfill several steps along the care continuum to 
achieve optimal clinical outcomes (Figure 1).1-3 Individuals should be screened for HIV; 
however, 20% of PLWH in the United States (US) are unaware of their diagnosis.4 Linkage 
to care is then necessary, but only 77% of individuals link to care.1-2, 5-6 Patients must 
remain in care; yet 50-75% of those linked to care meet the U.S. Health Resources and 
Services Administration (HRSA) retention criteria of ≥2 visits separated by 90 days in a 
year.2, 5, 7-10 Finally, PLWH need to receive and adhere to antiretroviral therapy (ART). 
Navigating all these steps is often unsuccessful:11 only 28% of those with HIV achieve 
virologic suppression.12
Linkage to care is a critical step in this process.13-15 However, no consistent definition of 
linkage to care exists. Prior studies have defined linkage to care as attending ≥1 clinic visit 
for HIV care within one to six months of diagnosis,16-35 or ≥2 visits within six to twelve 
months of diagnosis.36-38 Other researchers have used laboratory monitoring data--CD4 T-
cell counts and HIV-1 RNA levels--to investigate linkage to care, defining linkage as the 
occurrence of laboratory testing within one to six months of diagnosis,39-41 21 or more days 
after diagnosis,42 or within twelve months of diagnosis.43 In addition, governmental 
agencies and professional organizations differ in how they measure linkage. The US 
National HIV/AIDS Strategy defines linkage as laboratory testing within 90 days of 
diagnosis,44 while the Emergency Department National HIV Testing Consortium defines 
linkage as a clinic visit within 30 days of diagnosis.27
Linkage rates have similarly varied among single-clinic or multi-site cohort studies, from 
38% to 100%, depending on the linkage criteria used.45-46 Few studies have been 
community-based. A King County, Washington study examined the timing of linkage to 
HIV care countywide,47 but did not specifically address the predictive ability of linkage 
metrics. A recent study looked at the predictive ability of two linkage criteria (having either 
one or two laboratory tests within a year of diagnosis) for retention in care, but did not 
evaluate other linkage definitions.43
To effectively monitor and improve linkage to care, a better understanding of the predictive 
accuracy of linkage to care measures for retention and virologic suppression is necessary. To 
determine the diagnostic accuracy of linkage measures to predict retention in HIV care and 
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HIV virologic suppression, we compared clinic visit and laboratory testing based linkage 
measures using a city-wide cohort.
Methods
Data Sources and Study Population
The enhanced HIV/AIDS reporting system (eHARS)48 and the Ryan White CAREWare 
dataset (CAREWare) were combined. Philadelphia has used eHARS, a Centers for Disease 
Control and Prevention (CDC) database to which all new HIV diagnoses are reported, for 
mandated name-based case reporting since 2009. Local mandates require reporting of CD4 
T-cell counts <350 cells/ml and HIV-1 RNA levels to the Department of Public Health 
(DPH), which are electronically imported into eHARS.48 Thus, eHARS contains records of 
all PLWH who were diagnosed with HIV in Philadelphia, or who had CD4 T-cell counts 
<350 cells/ml or HIV-1 RNA levels drawn in Philadelphia.
Patients in the eHARS dataset were matched with records in CAREWare. eHARS and 
CAREWare records are routinely matched for surveillance via unique identification 
numbers contained in both datasets. All eligible patients (100%) identified in CAREWare 
were successfully matched to the eHARS database. CAREWare is free HIV care-monitoring 
software developed by HRSA for use by Ryan White Program (RWP) grantees and 
providers. Among its functions, it produces Ryan White HIV/AIDS Program Services 
Reports to meet HRSA reporting requirements. Patient-level data in CAREWare includes 
demographic, laboratory, pharmacy, and health service utilization information for all 
patients seen at Philadelphia RWP-funded clinics, collected to evaluate site-specific and 
system-wide performance data. Clinics perform chart reviews to abstract patient-level 
information. After undergoing quality control and verification, data is submitted to the DPH 
AIDS Activities Coordinating Office, where it is combined across clinics to produce a 
uniform database. Chart reviews and site visits verify the accuracy and completeness of the 
data. The majority of Philadelphia HIV clinics are RWP-funded, covering 71% of patients in 
care in Philadelphia (unpublished data, City of Philadelphia DPH). Therefore, all patients in 
all Philadelphia HIV clinics that receive RWP funding are in the CAREWare dataset. We 
performed retrospective analyses on PLWH linked to and retained in care at Philadelphia 
RWP-funded clinics.
The study population included all patients ≥18 years who were newly diagnosed with HIV 
in 2007 and 2008. All patients were residents of Philadelphia at the time of diagnosis. The 
study was approved by the Institutional Review Boards of the University of Pennsylvania 
Perelman School of Medicine and the City of Philadelphia DPH.
Predictor and Outcome Measures
We examined two sets of linkage to care measures based on the length of time between the 
individual's HIV/AIDS diagnosis date and first (1) HIV clinic visit or (2) laboratory 
monitoring test. Clinic visits were defined based on HRSA criteria: a visit to an outpatient 
provider with prescribing privileges (not including nurses, pharmacists, social workers, or 
other support services providers) in an HIV care setting.50 All linkage measures investigated 
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were used or adapted from prior studies (Figure 1).16-44, 49 Linkage measures included 
having a clinic visit within 30,26 60, 90,28-32 180,33-34 and 365 days after diagnosis;49 a 
clinic visit between 21 and 60 days, 21 and 90 days, 21 and 180 days, and 21 and 365 days 
after diagnosis;42 two clinic visits within 90, 180,33 and 365 days after diagnosis;49 and two 
clinic visits ≥90 days apart within 180 and 365 days after diagnosis.37 As an example, a 
patient diagnosed on July 1, 2007 who had a clinic visit 10 days after diagnosis would be 
considered to have had a clinic visit within 30, 60, 90, 180, and 365 days after diagnosis.
Laboratory tests were considered to be CD4 T-cell levels and HIV-1 RNA levels. Two 
laboratory tests performed on the same day were considered one test, and the test date refers 
to the date that the laboratory test was drawn. Laboratory tests were acquired from both 
eHARS and CAREWare. Laboratory-based linkage measures included having tests within 
30, 60, 90,40 180, and 365 days after diagnosis;43 between 21 and 60 days, 21 and 90 days, 
21 and 180 days, and 21 and 365 days after diagnosis;42 two tests within 90, 180, and 365 
days after diagnosis;43 and two tests 90 days apart within 180 and 365 days after 
diagnosis.36
Outcome variables used as reference standards included retention in care and virologic 
suppression, as the preferred outcome of linkage to care may differ depending on the 
organization (e.g. health department, clinic, community-based organization). For each 
patient, the linkage period of the study was defined as the day of diagnosis to 365 days after 
diagnosis, and the retention and virologic suppression period of the study was defined as 366 
days to 730 days after diagnosis. The length of follow-up was censored at 730 days after 
diagnosis in all patients. Retention measurement started 366 days after diagnosis to 
distinguish linkage from retention in care and was defined as ≥2 clinic visits for HIV care 
≥90 days apart between 366 and 730 days after diagnosis.50 Virologic suppression was 
defined as a viral load less than 200 copies/mL, as the last viral load sent between 366 and 
730 days after diagnosis.
Demographic variables are defined according to CDC criteria.48 Gender was defined as sex 
at birth. Race/ethnicity was categorized as white, black, Hispanic, or other. Exposure risk 
was grouped into heterosexual, men who had sex with men (MSM), injection drug use 
(IDU), and other/unknown. If a patient had both IDU and heterosexual exposures, or both 
IDU and MSM exposures, they were coded as having both risk factors.48 AIDS at time of 
HIV diagnosis was based on having a CD4 T-cell count <200 cells/μl, or an AIDS-defining 
condition.48 Place of birth was dichotomized as in the US vs. outside of the US, including 
Puerto Rico.48 Death within 730 days of diagnosis were identified by monthly evaluation of 
all death records that include HIV or AIDS on the death certificate and annual matching of 
eHARS records with the Social Security Death Index. CD4 T-lymphocyte count was 
categorized as <200 cells/ml, 200-350 cells/ml, 351-500 cells/ml, and >500 cells/ml.
Data Analysis
Univariate statistics described the dataset. Multivariate logistic regression models without 
repeated measures were used to assess relationships between linkage measures and the 
outcomes. Models were adjusted for age (continuous), gender, race/ethnicity, HIV risk 
factor, and AIDS at time of HIV diagnosis. We did not include CD4 T-lymphocyte counts 
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given the degree of colinearity with AIDS at time of HIV diagnosis. Adjusted odds ratios 
(AOR) with 95% confidence intervals (CI) are presented. Relationships were considered 
statistically significant at α<0.05.
Sensitivities, specificities, negative predictive values (NPV), and positive predictive values 
(PPV) were calculated for relationships between all linkage measures and outcome 
measures. Sensitivity for retention in care (and virologic suppression) was defined as the 
proportion of those meeting the retention in care criteria (or virologic suppression criteria) 
who were linked to care. Similarly, specificity for retention in care (and virologic 
suppression) was defined as the proportion of those not retained in care (or not virologically 
suppressed) who were not linked to care. PPV was defined as the proportion of those 
meeting linkage criteria who were retained in care (or virologically suppressed). NPV was 
defined as the proportion of those not meeting linkage criteria who were not retained in care 
(or not virologically suppressed). Receiver operating characteristic curves were created and 
the area under the curve (AUC) calculated to determine the ability of each metric to predict 
retention in care and virologic suppression. AUCs were adjusted for age, gender, race/
ethnicity, exposure risk, and AIDS at time of diagnosis.
We performed four sub- and sensitivity analyses: 1) to account for mortality, 2) to account 
for moving outside the city, 3) to determine the effect of clinic visits not captured in our 
dataset, and 4) to determine the effect of undetectable HIV viral loads not captured in our 
dataset. Since people who died or emigrated out of the city during the study period may not 
have had the opportunity to fulfill linkage, retention in care, and virologic suppression 
criteria, we conducted subanalyses (including sensitivities, specificities, PPVs, and NPVs) 
on only those individuals with complete follow-up to examine if excluding those who died 
or emigrated out of the city changed the point estimates, respectively. Next, sensitivity 
analyses addressing the 29% of PLWH in Philadelphia seen outside of RWP-funded clinics 
were performed, assuming all these individuals were linked to care. Finally, to account for 
the possibility of incomplete laboratory reporting, sensitivity analyses conducted based on 
the conservative estimate that 15% of PLWH (i.e., 50% of those not in care at RWP-funded 
clinics) had missing undetectable viral load measurements. Laboratory tests from two 
sources (eHARS and CAREWare) were available for 71% of patients. As such, sensitivity 
analyses assumed that half of those not in CAREWare were at risk of having missing 
undetectable HIV-1 RNA levels.
SAS Ver. 10.0 was used for all analyses (Cary, NC).
Results
Our cohort included 1781 patients. Most patients were male (70.1%) and black (63.3%), and 
had a heterosexual risk exposure (61.0%). Approximately one-third had AIDS at HIV 
diagnosis (34.5%) (Table 1). Linkage rates for clinic-based measures were applicable for 
RWP-funded clinics only, and ranged from 17.5% for having two visits in 180 days 
separated by 90 days, to 39.5% for having any visit within 365 days of diagnosis. For 
laboratory-based measures, linkage rates ranged from 34.0% for having two tests 90 days 
apart within 365 days, to 81.6% for having one test in 365 days (Table 2). Data and 
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diagrams representing progression through the HIV care cascade for each linkage metric are 
presented (Supplemental Digital Content [SDC]: Table 1 and Figures 1-28).51 Progression 
through the HIV care cascade, stratified by sociodemographic characteristics, are also shown 
(SDC Table 2).
Between 366 and 730 days after diagnosis, 780 patients (43.8%) successfully attended ≥1 
clinic visit, and 503 patients (28.2%) met the HRSA retention measure (two clinic visits ≥90 
days apart in one year). Similarly, 366-730 days after diagnosis, 23.5% (N=419) had 
virologic suppression. In total, 1108 patients (62.2%) were neither retained in care nor had 
virologic suppression 366-730 days after diagnosis.
Using retention in care as the outcome of appropriate linkage, the measure with the highest 
PPV for retention was attending two clinic visits ≥90 days apart within 365 days of 
diagnosis (74.2%; 95% CI: 70.8%-78.0%). The linkage measure with the lowest PPV for 
retention was laboratory monitoring within 30 days (32.0%; 95% CI: 29.1%-34.9%). PLWH 
who did not have a clinic visit between 21 and 365 days after diagnosis had the highest NPV 
for retention in care (94.5%, 95% CI: 0.928-0.962), while the absence of laboratory 
monitoring within 30 days of diagnosis had the lowest NPV for retention (77.0%, 95% CI: 
74.0%-80.0%). The measure with the highest AUC for retention in care was attending a 
clinic visit between 21 and 365 days after diagnosis (Table 3).
Using virologic suppression as the outcome of appropriate linkage, the measure with the 
highest NPV for virologic suppression was lacking laboratory testing within 365 days of 
diagnosis (98.2%; 95% CI: 96.1%-99.3%) and the measure with the lowest NPV was the 
absence of a clinic visit within 30 days of diagnosis (87.0%, 95% CI: 85.0%-89.0%). The 
measure with the lowest PPV for virologic suppression was having two tests in 180 days 
separated by 90 days (41.0%, 95% CI: 37.0%-45.0%), while having two visits in 180 days 
separated by 90 days had the highest PPV for virologic suppression (49.0%, 95% CI: 
43.0%-55.0%). Patients completing two laboratory tests separated by 90 days in 365 days 
had the highest AUC for virologic suppression (Table 4).
Sensitivity analyses were performed to account for care received outside of RWP-funded 
clinics. Linkage measures associated with the highest and lowest odds of retention in care, 
sensitivities, specificities, NPVs, and PPVs did not change. Sensitivity analyses were also 
performed to account for the possibility of unreported undetectable viral loads. NPVs and 
PPVs did not differ greatly. When sensitivity analyses were performed assuming both 
laboratory monitoring-based measures and the outcome measure of virologic suppression 
were underestimated, PPV changed little, but NPV decreased to as little as 11% for having 
any laboratory test sent within 365 days (SDC, Tables 3-6).
Additional analyses were performed to determine the effect of mortality on estimates. Point 
analyses of those alive at 730 days after diagnosis did not differ by 10% of their baseline. 
We also performed subanalyses examining only those patients who did not move out of 
Philadelphia during the study. Point analyses did not differ by 10% of their baseline.
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This is one of the first studies comparing multiple laboratory and clinic-based measures of 
linkage to care. Clinic-based linkage measures, in particular completing ≥1 clinic visits 
between 21 and 365 days after diagnosis, best predict retention in care. On the other hand, 
completing two laboratory tests separated by 90 days within 365 days of diagnosis best 
predicts virologic suppression. These data suggest that both clinic and laboratory-based 
linkage measures have value. Selection of a linkage measure should be tailored to the 
outcome of interest.
Government agencies and professional organizations vary in criteria used to define linkage 
to care. The Emergency Department National HIV Testing Consortium metric is a clinic 
visit within 30 days of diagnosis.27 In our study, only 62.3% of patients meeting this 
measure were retained in care, and only 40.5% achieved virologic suppression. The US 
National HIV/AIDS Strategy recommends linking 85% of persons to care within 90 days of 
diagnosis, using a laboratory-based measure.47 While 72.0% of patients met this measure, 
only 32.5% were retained, and 27.7% achieved virologic suppression. Using the linkage 
metric most predictive of retention in care, 38.2% of patients completed a clinic visit 
between 21 and 365 days after diagnosis, with 65.0% of patients meeting this measure 
retained in care. Alternatively, using the linkage metric most predictive of virologic 
suppression, 56.3% of patients had two laboratory tests 90 days apart within 365 days of 
diagnosis, and 38.0% of these achieved virologic suppression. Our data suggest that 
agencies and organizations should consider which linkage metrics best meet their outcomes 
of interest when recommending linkage criteria.
Laboratory-based linkage measures had lower predictive abilities for retention in care than 
clinic-based measures. 81.6% of the population had a laboratory test within 365 days of 
diagnosis, while only 39.5% had a clinic visit within the Ryan White system within 365 days 
of diagnosis. Clinic visits were underreported to a greater extent than laboratory testing, as 
we used the HRSA definition for HIV clinic visits50 (which excludes pharmacy, nursing, 
social work, and other visits to providers without prescribing privileges), and as we were 
unable to detect visits to non-RWP-funded clinics. Furthermore, laboratory testing may 
occur outside of the primary HIV care setting, including in non-HIV clinics, inpatient 
hospitals, and emergency departments. Our data differs from recent studies suggesting the 
use of laboratory testing as a proxy for clinic visits.52 While using laboratory tests as a 
proxy for clinic visits may be helpful in clinic cohort-based studies,52 our data suggest that 
laboratory tests may not be as predictive of clinic visits in all settings, such as surveillance.
Prior studies have evaluated metrics for retention in care53-54 and predictors of virologic 
suppression.55 However, few studies have examined how well different linkage metrics 
predict retention in care or virologic suppression. Among these, only one41 or two43 linkage 
metrics were compared. We present a more complete picture of linkage to care, retention in 
care, and virologic suppression than prior clinic cohort-based studies.
Our study had limitations. First, generalizability was limited as we only studied patients in 
one US city. Also, linkage, retention, and virologic suppression are lower than reported 
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elsewhere.2, 5, 45-46, 56-59 For example, a meta-analysis of 28 studies estimated that 77% of 
patients are linked to care, 51% are retained in care, and 35% achieve virologic 
suppression.2, 5 Linkage rates in our study ranged from 17.5% to 81.6%, 28.2% of patients 
were retained in care, and 23.5% achieved virologic suppression. Our inability to access 
clinic visit data on patients seen outside RWP-funded clinics would have underestimated 
linkage to and retention in care for the metrics that used this data. However, sensitivity 
analyses accounting for PLWH not attending RWP-funded clinics demonstrated that the 
linkage metrics most predictive for retention in care and virologic suppression did not 
change. If laboratories were not reporting undetectable HIV-1 RNA levels, we also may 
have underestimated virologic suppression. Sensitivity analyses accounting for this did not 
alter the results. We also performed sensitivity analyses to account for those who died or 
migrated out of the city. While it is possible that PLWH in care may lack laboratory 
monitoring, this is rare (unpublished data, Philadelphia DPH). Similarly, it is unlikely that 
PLWH not in care would achieve virologic suppression.
We focused on virologic suppression and retention in care between 366 and 730 days after 
diagnosis to differentiate linkage to care from retention in care, as some researchers defined 
linkage to care within the first 365 days after diagnosis.38 Some patients may have dropped 
out of care prior to this time, potentially contributing to the lower retention rates seen in the 
study. In addition, we did not collect data on the timing of ART initiation, which has been 
associated with both improved retention in care and virologic suppression.60-61 Low rates of 
ART initiation among PLWH in our cohort could further lower the proportion of patients 
not meeting retention in care and virologic suppression targets.
Despite these adjustments, linkage and retention metrics were still lower than reported 
elsewhere.2, 5, 45-46, 56-59 Our data came from a large city with many racial minorities and 
persons below the poverty line, which may be associated with lower rates of retention in 
care. Care provider characteristics may also differ from other cities. For example, providers, 
including non-HIV providers working in urgent care, emergency, inpatient, and primary care 
clinic settings, may be less likely to send laboratory tests than in other regions, lowering 
laboratory-based linkage rates. Further studies are needed to evaluate how linkage measures 
perform in other locals and settings.
Understanding the predictive ability of measures of linkage to care is necessary for 
improving the quality of HIV care and reducing HIV transmissions. Our data suggests that 
selection of the ideal linkage measure depends on the outcome of interest being evaluated. 
The clinic-based measure of completing a visit between 21 and 365 days after diagnosis best 
predicted retention in care, and may be useful for testing centers focused on referring PLWH 
to care. Meanwhile, the laboratory-based measure of completing two laboratory tests 
separated by 90 days within 365 days of diagnosis best predicted virologic suppression, and 
may be a helpful definition for test-and-treat strategies aimed at reducing community viral 
load. Researchers studying retention and virologic suppression in PLWH, testing agencies 
seeking to improve the quality of their work, and funding agencies deciding how to allocate 
resources should tailor linkage measures based on the outcome of interest.
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Cascade adapted from: Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in 
medical care among HIV-diagnosed persons: a meta-analysis. AIDS. 2010; 24:2665-2678 
and Centers for Disease Control and Prevention. Vital signs: HIV prevention through care 
and treatment—United States. MMWR. 2011; 60:1618-1623.
Linkage to care metrics examined are listed in the table and are based on clinic visits or 
laboratory tests. Visits refer to clinic visits for HIV care; i.e., an outpatient visit with a 
provider with prescribing privileges in an HIV care setting. Either a CD4 T-cell count or 
HIV-1 RNA level was considered a laboratory test. Laboratory tests drawn on the same day 
were counted as one test. The date of the laboratory test was the date that the laboratory test 
was drawn, regardless of when it was entered into the database. Retention in care was 
defined as two clinic visits spaced 90 days apart between 366 and 730 days after diagnosis. 
Virologic suppression was defined as a HIV-1 RNA level <200 copies/ml, between 366 and 
730 days after diagnosis.
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Table 1
Demographic characteristics of 1781 newly-diagnosed HIV-positive persons in the City of Philadelphia, 2007 
and 2008.
Characteristic Number (Percentage)
Age (years): Mean (Standard deviation) (no missing) 37.0 (12.2)
Female Gender (no missing) 532 (29.9)
Race/ethnicity (no missing)
        Black 1128 (63.3)
        White 308 (17.3)
        Hispanic
* 269 (15.1)
        Other 76 (4.3)
HIV risk exposure
        Heterosexual exposure 1082 (61.0)
        Injection Drug Use exposure 304 (17.1)
        Men who have Sex with Men exposure 597 (33.7)
        Other/Missing 27 (1.5)
Born inside the U.S. 1588 (89.3)
        Missing location of birth 2 (0.11)
Diagnosed with AIDS at time of HIV diagnosis (no missing) 615 (34.5)
CD4 T-cell count within 90 days of diagnosis
        CD4 count at diagnosis ≤200/ml 615 (34.5)
        CD4 count at diagnosis >200 and ≤350/ml 189 (10.6)
        CD4 count at diagnosis <350 and ≤500/ml 191 (10.7)
        CD4 count at diagnosis >500/ml 386 (21.7)
        No CD4 count sent within 90 days of diagnosis 400 (22.5)
Death within 2 years of HIV diagnosis (no missing)† 94 (5.3)
Migrated outside Philadelphia during study 105 (5.9)
        Missing information on migration 60 (3.4)
*
Patients who identified as both Hispanic and another race were considered Hispanic.
†
Deaths are identified by monthly evaluation of all death records that include HIV or AIDS on the death certificate and annual matching of eHARS 
records with State Vital Statistics data, the Social Security Death Index, and the National Death Index. Patients who died within 730 days of HIV 
diagnosis were included in this variable.
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Table 2
Number and percentage of newly-diagnosed HIV-positive persons meeting linkage metrics, with odds ratios 
(OR) describing the likelihood of meeting retention in care criteria, of 1781 persons newly diagnosed with 
HIV in Philadelphia in 2007 and 2008.
*
Linkage Measure Number Meeting Linkage Measure 
(percentage)
Adjusted OR for Retention in Care (95% CI)
Visit in 30 Days 363 (20.4) 6.4 (5.0-8.3)
Visit in 60 days 473 (26.6) 9.2 (7.2-11.7)
Visit in 90 days 530 (29.8) 10.6 (8.3-13.6)
Visit in 180 days 614 (34.5) 15.8 (12.2-20.5)
Visit in 365 days 703 (39.5) 30.9 (22.6-42.3)
Visit between 21 days and 60 days 391 (22.0) 8.3 (6.4-10.6)
Visit between 21 days and 90 days 473 (26.6) 10.0 (7.8-12.8)
Visit between 21 days and 180 days 576 (32.3) 15.1 (11.7-19.5)
Visit between 21 and 365 days 680 (38.2) 31.0 (22.8-42.2)
Two visits in 90 days 384 (21.6) 9.6 (7.4-12.4)
Two visits in 180 days 496 (27.9) 14.8 (11.4-19.1)
Two visits in 365 days 610 (34.3) 25.8 (19.5-34.2)
Two visits in 180 days, separated by 90 days 312 (17.5) 11.6 (8.7-15.9)
Two visits in 365 days, separated by 90 days 508 (28.5) 25.1 (19.1-33.0)
Tests in 30 days 1014 (56.9) 1.5 (1.2-1.9)
Tests in 60 days 1205 (67.7) 1.9 (1.5-2.4)
Tests in 90 days 1282 (72.0) 2.3 (1.8-3.0)
Tests in 180 days 1382 (77.6) 4.5 (3.2-6.4)
Tests in 365 days 1454 (81.6) 8.6 (5.3-14.0)
Tests between 21 and 60 days 643 (36.1) 2.4 (1.9-3.0)
Tests between 21 and 90 days 818 (45.9) 2.9 (2.3-3.6)
Tests between 21 and 180 days 1075 (60.3) 5.5 (4.3-7.3)
Tests between 21 and 365 days 1226 (68.8) 11.6 (7.8-17.3)
Two tests in 90 days 370 (37.6) 4.2 (3.4-5.3)
Two tests in 180 days 954 (53.6) 6.2 (4.8-8.1)
Two tests in 365 days 1139 (64.0) 11.4 (8.0-16.4)
Two tests in 180 days, separated by 90 days 605 (34.0) 3.7 (3.0-4.7)
Two tests in 365 days, separated by 90 days 1003 (56.3) 9.9 (7.3-13.4)
Abbreviations: OR: odds ratios; CI: confidence interval; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome
*
Retention in care defined as two clinic visits spaced 90 days apart in one year, between 366 and 730 days after diagnosis. Visits refer to clinic 
visits for HIV care; i.e., an outpatient visit with a provider with prescribing privileges in an HIV care setting. Logistic regression was used to 
determine relationships between the linkage metric and the likelihood of meeting retention in care criteria. ORs were adjusted for age, gender, race/
ethnicity, HIV exposure group, and AIDS at time of HIV diagnosis. Tests refer to laboratory tests drawn, including CD4 T-cell counts and HIV-1 
RNA levels. Either a CD4 T-cell count or HIV-1 RNA level was considered a laboratory test. If two laboratory tests were drawn, these must have 
been drawn on separate days. The date of the laboratory test was the date that the laboratory test was drawn, regardless of when it was entered into 
the database.
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